急性髓系白血病的细胞治疗进展  

The review of cell therapy in acute myeloid leukemia

作　　者：杨慧 姚浩 陈丹 Yang Hui;Yao Hao;Chen Dan(Department of Hematology,the General Hospital of Western Theater Command of Chinese People's Liberation Army,Chengdu 610083,China)

机构地区：[1]中国人民解放军西部战区总医院血液科,成都610083

出　　处：《中华细胞与干细胞杂志（电子版）》2021年第5期311-316,共6页Chinese Journal of Cell and Stem Cell（Electronic Edition）

基　　金：西部战区总医院学科助推基金(41732E7);西部战区总医院院管课题孵化项目(2021-XZYG-C45);西部战区总医院院管课题面上项目(2021-XZYG-B32)。

摘　　要：急性髓系白血病(AML)是一种异质性疾病,与广泛的基因型改变有关,长期的疾病控制需要多种治疗方法。在过去的3~5年中,随着对基因突变的理解和分子特异性认识的提高,基于基因水平的AML靶向细胞治疗迅速发展。目前,利用细胞免疫疗法治疗AML的基础和临床研究已取得不断进展,其中包括自然杀伤(NK)、细胞因子诱导型杀伤(CIK)、嵌合抗原受体T细胞(CAR-T)、肿瘤相关抗原淋巴细胞(TAA-T)和T细胞受体(TCR)修饰型T细胞、CAR-NK和CAR-CIK等细胞治疗,靶基因主要选择CD33、CD123及CLEC12A等髓系抗原。本文综述了以上AML细胞治疗的现状及展望。Acute myeloid leukemia(AML)is a heterogeneous disease associated with a wide range of genotypes variations.And we know that the disease with long term requires multiple therapeutic approaches to control it.In the past 3~5 years,gene-level AML-targeted cellular therapies have rapidly improved as understanding of genetic mutations and molecular specificity.And continuous progress has been made in basic and clinical research on the use of cellular immunotherapy for AML,including natural killer(NK),cytokine-induced killing(CIK),chimeric antigen receptor T cells(CAR-T),tumor-associated antigen lymphocytes(TAA-T)and T-cell receptor(TCR)-modified T cells,as well as CAR-NK,CAR-CIK and other cell therapies.And for these treatments,the target genes mainly selected from myeloid antigens such as CD33,CD 123 and CLEC12A.The current status and prospects of cell therapy in AML were reviewed in this article.

关 键 词：细胞治疗 嵌合抗原受体T细胞 自然杀伤细胞 细胞因子诱导杀伤细胞 急性髓系白血病 

分 类 号：R733.71[医药卫生—肿瘤]